KZIA · Kazia Therapeutics Ltd
$12.49
-0.20 (-1.58%)
At close · Jul 29
Market Cap
$145.01M
Shares
11.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.69
Open$12.25
Day$11.54–12.85
52W$4.86–17.40
Avg vol 30d170K
Short int740K · 6.5% float · 4.1d
Short vol61%
DataJan 2020–Jul 2026
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
62%
mid-range
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+105%
trailing
YTD return
+84%
this year
Relative strength
+97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Distributing
4 of 23 funds reported for Jun 30 · net -52.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.48% of float · ▲ +14.6% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 1-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
123%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Distributing
4 of 23 funds reported for Jun 30 · net -52.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.48% of float · ▲ +14.6% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $13 · 62%
52-wk high $17
vs 200-day avg +31%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KZIA
this stock
Kazia Therapeutics Ltd
|
$145.01M | +84.2% | — | — | 6.5% |
|
ONC
BeOne Medicines Ltd.
|
$473.24B | +7.3% | +22179.2% | 963.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KZIA | -6.4% | -10.8% | +104.7% | -9.9% | +84.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.4% | -10.7% | +97.2% | -9.1% | +75.5% |